MC-8591 could be a future option for the treatment and prevention of HIV

Merck MK-8591 is an experimental antiretroviral agent that maintains drug levels that are able to inhibit HIV for up to 6 months after dosing and could represent a prophylactic and therapeutic "paradigm shift" in HIV patients, according to Merck. with the research presented in the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016) in Boston.

Jay Grobler of Merck reported that a single oral dose of MK-8591 maintained suppressed the simian immunodeficiency virus (SIV) with undetectable viral load in monkeys and was effective in keeping the body so for a week after dosing. The researchers also evaluated an oral dose of the drug in HIV-negative individuals whose diagnoses showed that the cellular levels of the drug were sufficient to suppress HIV and that this suppression could be maintained in the long run. Preliminary research results involving people with HIV were also encouraging. A formulation of the injected drug maintained excellent cellular levels for more than 6 months when administered in rodents.

Killer cells are white blood cells of the immune system that has the function of killing diseased cells, such as cancer, for example, or to mark them are exteminadas by other antigens. They are also known to Killer T-cells (T-Assssinas)
Killer cells are white blood cells of the immune system that has the function of killing diseased cells, such as cancer, for example, or to mark them are exteminadas by other antigens. They are also known to Killer T-cells (T-Assssinas)

The development of antiretroviral agents that require less frequent dosing have the potential to increase adherence to HIV treatment and use of anti-HIV drugs, such as Prevention (TasP) or PrEP.

MK-8591 is a reverse transcriptase inhibitor nucleoside (NRTIs) in the early stages of development. The drug's properties show that it has prolonged persistence in human peripheral blood mononuclear cells (PBMCs) and macrophages. Laboratory tests showed that these cells were protected against infection with HIV, even in the absence of continued antiretroviral exposure.

In the study presented in CROI, SIV-infected rhesus monkeys received weekly MK-8591 oral therapy, with doses ranging from 1,3 to 18,2 mg / kg. Plasma viral load was measured by post-dose 42 pre-dose dosing. Concentrations of MK-8591 were also evaluated throughout this period.

The researchers used the results from the animal study to select a weekly oral dose for evaluation in HIV-negative patients.

SIV viral load line in monkeys was between 106 to 108 copies / ml. After dosing with MK-8591, collective thicknesses with viral load below 108 copies / mL has fallen by up to 2macaco%2Bengra%25C3%25A7ado14-300x400 log in viral load, with suppression sustained for at least 7 days. Agent concentrations in 0,53 pmol / 10 experimental PBMCs6 and above were associated with maximum drop in viral load within one week after dosing.

In the study involving HIV-negative individuals, doses of 10 mg were able to achieve optimal drug levels required to prolong viral suppression. The drug was well tolerated.

The researchers also presented data from an early clinical trial involving people with HIV. These showed that a single oral dose 10 mg resulted in a drop log in 1.6 viral load for days 7 to 10. Intracellular levels of the drug were good and there were no signs of resistance.

An injected long-acting MK-8591 formulation continuously provided sufficient levels continuously, extending drug release in rodents. Plasma levels were similar to those observed in monkeys and humans, with drug release for periods longer than 6 months.

The researchers believe their findings show the potential for oral weekly dosing of MK-8591.

Formulations of long-acting (injected) oral and parenteral MK-8591 with potential for 6 months or longer "would represent a potential paradigm shift as a single agent for the prevention of HIV infection or as a component of a long dosing regimen for the treatment of HIV, "the researchers concluded. "Ongoing studies suggest the potential to provide coverage for periods of up to 1 year."

Translated into 16 April 2016 by Claudio Souza the original CROI 2016: Long-Acting MK-8591 Could Be Future Option for HIV Treatment and Prevention Written by Michael Carter on HIV and Hepatitis em collaboration with

reviewed by Mara T Macedo


J Grobler, and Friedman, SE Barrett, et al. Long-Acting oral and parenteral dosing of MK-8591 for the treatment of HIV or prophylaxis Jay Grobler. Conference on retroviruses and opportunistic infections. Boston, February 22-25, 2016. abstract 98.

Have you received your diagnostic reagent and are you scared? Do you think your life is over? Are you having thoughts "of the type clueless"?

You need to get your hopes up!

Understand that my resilience was built one day at a time, one illness after another, one SUSAN AFTER THE OTHER!

Resilience is not something you are born with! You ROW IT! One fall after another. For every fall inevitably follows a new rebound!

In summary:

get up

Shake the dust off!

And Turn Around!

Your doctor, your doctor can do a lot for you!

Your family, if you have any, because there is not one left for me, they can or can not do something for you.

God could do everything for you!

But it's up to you to decide to go ahead or sit on the curb!

Do you think I talk too much? Please read my outdated medical history! 🙂 It may take a little while!

And as for Health, it is a Right of All and a Duty of the State


Related Publications

Comment and Socialize. Life is better with friends!

This site uses Akismet to reduce spam. Learn how your comment is processed.

Soropositivo.Org, and Automattic do everything within our reach with regard to your privacy. You can learn more about this policy in this link I accept the Privacy Policy of Soropositivo.Org Read All in Privacy Policy

%d bloggers like this: